Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient
Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient
复制标题
DOI：
10.1111/j.1365-2141.2011.08837.x
复制
发表时间：
2012-01
影响因子：
6.5
通讯作者：
N. Rao;C. Butcher;I. Lewis;D. Ross;J. Melo;H. Scott;P. Bardy;R. D’Andrea
中科院分区：
文献类型：
--
作者：
N. Rao;C. Butcher;I. Lewis;D. Ross;J. Melo;H. Scott;P. Bardy;R. D’Andrea
P210蛋白。美国国家科学院院刊，85，9312-9316。新泽西州多纳托，Fang，D.，Sun，H.，Giannola，D.，Peterson，L.F. & Talpaz，M.（2010）伊马替尼敏感和耐药慢性髓性白血病中极光激酶抑制剂MK-1457（VX-680）细胞反应的靶点和效应物。Biochemical Pharmacology，79，688-697. Fischle，W.，曾理学士，Dormann，H. L.，Ueberheide，B.M.，加西亚，文学士，Shabanowitz，J.，亨特，D.F.，Funabiki，H. & Allis，C.D.（2005）通过组蛋白H3甲基化和磷酸化调节HP 1-染色质结合。Nature，438，1116-1122. Gontarewicz，A.，Balabanov，S.，Keller，G.，Panse，J.，Schafhausen，P.，Bokemeyer，C.，菲尔德，W.，Moll，J. & Brummendorf，T.H.（2008）PHA 680626通过抑制Bcr-Abl酪氨酸激酶和Aurora激酶对伊马替尼抗性慢性髓性白血病细胞系和原代CD 34细胞表现出抗增殖和促凋亡活性。Leukemia Research，32，1857- 1865.斯图尔特，医学博士，Li，J. & Wong，J.（2005）组蛋白H3赖氨酸9甲基化、转录抑制和异染色质蛋白1募集之间的关系。分子和细胞生物学，25，2525-2538。杨，硕士，Shah，N.P.，赵先生，Seeliger，M.，Milanov，Z.V.，Biggs，III，W.H.，Treiber，D.K.，Patel，H.K.，Zarrinkar，P.P.，新泽西州洛克哈特Sawyers，C.L. & Kuriyan，J.（2006）Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Research，66，1007- 1014. Zippo，A.，塞拉菲尼，R.，Rocchigiani，M.，Pennacchini，S.，Krepelova，A. & Oliviero，S. H3 S10 ph和H4 K16 ac之间的组蛋白串扰产生介导转录延伸的组蛋白代码。Cell，138，1122-1136.
P210 protein. Proceedings of the National Academy of Sciences the United States of America, 85, 9312–9316. Donato, N.J., Fang, D., Sun, H., Giannola, D., Peterson, L.F. & Talpaz, M. (2010) Targets and effectors of the cellular response to aurora kinase inhibitor MK-1457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. Biochemical Pharmacology, 79, 688–697. Fischle, W., Tseng, B.S., Dormann, H.L., Ueberheide, B.M., Garcia, B.A., Shabanowitz, J., Hunt, D.F., Funabiki, H. & Allis, C.D. (2005) Regulation of HP1-chromatin binding by histone H3 methylation and phosphorylation. Nature, 438, 1116–1122. Gontarewicz, A., Balabanov, S., Keller, G., Panse, J., Schafhausen, P., Bokemeyer, C., Fielder, W., Moll, J. & Brummendorf, T.H. (2008) PHA680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34 cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. Leukemia Research, 32, 1857– 1865. Stewart, M.D., Li, J. & Wong, J. (2005) Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment. Molecular and Cellular Biology, 25, 2525–2538. Young, M.S., Shah, N.P., Chao, L.H., Seeliger, M., Milanov, Z.V., Biggs, III, W.H., Treiber, D.K., Patel, H.K., Zarrinkar, P.P., Lockhart, D.J., Sawyers, C.L. & Kuriyan, J. (2006) Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Research, 66, 1007– 1014. Zippo, A., Serafini, R., Rocchigiani, M., Pennacchini, S., Krepelova, A. & Oliviero, S. (2009) Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. Cell, 138, 1122–1136.